allogeneic pancreatic islet cells
Cell therapyexperimental
The pancreatic islets or islets of Langerhans are the regions of the pancreas that contain its endocrine (hormone-producing) cells, discovered in 1869 by German pathological anatomist Paul Langerhans. The pancreatic islets constitute 1–2% of the pancreas volume and receive 10–15% of its blood flow. The pancreatic islets are arranged in density routes throughout the human pancreas, and are important in the metabolism of glucose. — Wikipedia
Clinical trial activity
60 trials · 48 clinical orgs · 0 marketing orgs
Phase 1
29
Phase 2
45
Phase 3
4
Phase 4
0
Earliest trial started Sep 1, 2000 (NCT00285233)
Timeline
Indications
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPancreatic islets ↗
Also known as
- allogeneic islet cells
- allogeneic islets of langerhans
- allogeneic pancreatic islet cells
- allogenic human islet cells
- allogenic human purified pancreatic islets
- allogenic islet cells
- human islets
- human pancreatic islet
- human pancreatic islets
- islet cells
- islet of langerhans
- islets of langerhans
- pancreatic islets
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07118475 | Early Phase 1 (Phase 1) | Aug 18, 2025 | Fudan University |
| NCT06651515 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | Seraxis |
| NCT06751199 | N/A | Dec 30, 2024 | Second Military Medical University |
| NCT05990517 | Phase 2 | Feb 22, 2023 | Jiao Tong University |
| NCT05990530 | Phase 2 | Feb 22, 2023 | Jiao Tong University |
| NCT05480657 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Eledon Pharmaceuticals |
| NCT03977662 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2019 | California Institute for Regenerative Medicine (CIRM), University of California, San Francisco |
| NCT03746769 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2019 | City of Hope National Medical Center, University of California, Los Angeles |
| NCT03698396 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2018 | University of Virginia |
| NCT02846571 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Bascom Palmer Eye Institute, University of Miami |
| NCT02464878 | Phase 2 | Jan 1, 2017 | Harvard University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Iowa |
| NCT02803905 | Phase 2 | Apr 1, 2016 | The Foundation Institute San Raffaele G. Giglio of Cefalù, Vita-Salute University of Milano. Italy |
| NCT02505893 | Phase 2 | Apr 1, 2015 | Fondazione Italiana Diabete Onlus, Vita-Salute University of Milano. Italy |
| NCT02402439 | Phase 1 | Dec 1, 2014 | University of California, San Francisco |
| NCT02213003 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2014 | Juvenile Diabetes Research Foundation, University of Miami |
| NCT01909245 | Phase 2 | Oct 1, 2013 | City of Hope National Medical Center, University of California, Los Angeles, Virginia Mason Medical Center |
| NCT02872571 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | University of Lille |
| NCT01897688 | Phase 3 | Jun 1, 2012 | Northwestern University |
| NCT01722682 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2012 | Government of Italy, Vita-Salute University of Milano. Italy |
| NCT01606475 | N/A | May 23, 2012 | University of Minnesota |
Showing 20 of 60 trials
Page 1 / 3
Organizations
Research & Development (48)
48 organizations
Page 1 / 3